Australia & Optimi Health
7 shared events · Importance 3 · Last updated Sep 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Australia: Australia is the recipient country for Optimi Health's psilocybin capsules, providing a regulated market for the treatment of treatment-resistant depression and setting a model for psychedelic medicine use.
Optimi Health: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.
Jun 29, 2026 · 12 articles
Business
Australia: Australia is currently a commercial market where Optimi Health's 5mg psilocybin capsules are prescribed to patients for treatment-resistant depression, demonstrating an existing successful market for the company's products.
Optimi Health: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.
Jun 02, 2026 · 25 articles
Tech
Australia: Australia is a market where Optimi Health Corp.'s 5mg psilocybin formulation is already commercially prescribed for treatment-resistant depression under the country's Authorized Prescriber Scheme.
Optimi Health: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.
Jun 16, 2026 · 11 articles
Business
Australia: Australia is cited as a market where Optimi Health products are prescribed to patients under the Authorized Prescriber Scheme, illustrating the company's international reach.
Optimi Health: Optimi Health is the central entity of the event, announcing its participation in the H.C. Wainwright 28th Annual Global Investment Conference and making its presentation available on demand from September 11, 2026. The event offers the company a platform to engage investors, though no financial or clinical news was disclosed.
Sep 08, 2026 · 6 articles
Business
Australia: Optimi's products are prescribed to patients in Australia under the Authorized Prescriber Scheme, representing a current market for its psychedelic therapies.
Optimi Health: The company made the appointment to strengthen its clinical development capabilities ahead of planned Phase 2 psilocybin and Phase 3 MDMA trials. The move supports its pipeline but has limited near-term financial impact.
Sep 22, 2026 · 7 articles
Tech
Australia: Australia is mentioned as a market where Optimi's products are prescribed under the Authorized Prescriber Scheme, indicating existing international reach. It is not directly involved in the trial.
Optimi Health: Optimi Health is the central entity initiating the Phase 2 trial, which represents its largest clinical commitment to date and a strategic step toward potential drug registration. The trial could enhance its pipeline and market positioning, though it carries development risks and no near-term revenue.
Sep 10, 2026 · 15 articles
Business
Optimi Health: Optimi Health completed the first 2026 production and export of MDMA and psilocybin capsules to Australia, expanding its market access for psychedelic treatments for PTSD and TRD.
Jan 26, 2026 · 6 articles
60
Optimi Health supplied Australian clinics AustraliaOptimi Health Phase 2...
ERGEN INTELLIGENCE
Explore this relationship live
Track how Australia and Optimi Health interact across events, view sentiment trends, and discover connected entities.
Open Dashboard